Phase III study of ixazomib in multiple myeloma fails to meet primary endpoint
In the TOURMALINE-MM2 clinical trial, the addition of ixazomib to lenalidomide and dexamethasone did not result in a statistically significant improvement in progression-free survival in patients with newly diagnosed multiple myeloma.
Source:
Biospace Inc.